Valuation: Alvotech

Market Cap 1.89B 1.63B 1.54B 1.4B 2.62B 180B 2.63B 18.29B 7.03B 91.77B 7.09B 6.94B 290B P/E 2026 *
102x
P/E 2027 * 17.8x
Enterprise Value 2.96B 2.55B 2.42B 2.19B 4.11B 283B 4.13B 28.73B 11.05B 144B 11.14B 10.89B 455B EV / Sales 2026 *
4.5x
EV / Sales 2027 * 3.8x
Free-Float
39.95%
Yield 2026 *
-
Yield 2027 * -
1 day+0.95%
1 week-0.56%
Current month+1.93%
1 month+29.34%
3 months+26.86%
6 months+52.45%
Current year+3.12%
1 week 5.06
Extreme 5.06
5.39
1 month 3.75
Extreme 3.75
5.47
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.25
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap. Importance
1/4/26 Free

Chief Executive Officer

117,271 0.0355%
1/4/26 Sell

Founder

318,000 0.0963%
1/4/26 Buy

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-0.56%-34.12%-40.43% 1.89B
+1.34%-4.07%-1.72%+9.91% 45.48B
+0.21%-2.98%+337.74%+520.30% 43.68B
+1.74%-2.24%+39.82%+20.85% 43.09B
+1.38%-3.28%+6.84%+73.19% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+108.58% 16.4B
+3.08%+1.79%+15.54%+32.22% 14.24B
+1.93%-3.55%+82.00%+36.66% 13.28B
Average +1.08%-2.93%+52.76%+89.01% 26.67B
Weighted average by Cap. +0.95%-3.48%+74.25%+123.82%

Financials

2026 *2027 *
Net sales 659M 568M 538M 488M 915M 62.99B 919M 6.39B 2.46B 32.05B 2.48B 2.42B 101B 776M 668M 633M 574M 1.08B 74.11B 1.08B 7.52B 2.89B 37.7B 2.91B 2.85B 119B
Net income 30.36M 26.16M 24.77M 22.45M 42.12M 2.9B 42.33M 294M 113M 1.48B 114M 112M 4.66B 109M 94.01M 89.01M 80.68M 151M 10.42B 152M 1.06B 407M 5.3B 410M 401M 16.76B
Net Debt 1.08B 928M 879M 796M 1.49B 103B 1.5B 10.43B 4.01B 52.34B 4.04B 3.96B 165B 1.06B 911M 862M 782M 1.47B 101B 1.47B 10.24B 3.94B 51.38B 3.97B 3.88B 162B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
11/09/26 US$5.290 +0.95% 667,872
10/09/26 US$5.240 +0.58% 540,857
09/09/26 US$5.210 +0.39% 572,359
08/09/26 US$5.190 -2.44% 632,635
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
5.290USD
Average target price
6.000USD
Spread / Average Target
+13.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!